| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4748858
Max Phase: Preclinical
Molecular Formula: C21H24ClF2N3O2
Molecular Weight: 423.89
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: Cc1ccc(OCCNCC2(F)CCN(C(=O)c3ccc(F)c(Cl)c3)CC2)nc1
Standard InChI: InChI=1S/C21H24ClF2N3O2/c1-15-2-5-19(26-13-15)29-11-8-25-14-21(24)6-9-27(10-7-21)20(28)16-3-4-18(23)17(22)12-16/h2-5,12-13,25H,6-11,14H2,1H3
Standard InChI Key: LMUCVWASWOAHCM-UHFFFAOYSA-N
Associated Targets(Human)
DRD2 Tclin Dopamine D2 receptor (23596 Activities)
HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Adra1b Adrenergic receptor alpha-1 (5652 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 423.89 | Molecular Weight (Monoisotopic): 423.1525 | AlogP: 3.80 | #Rotatable Bonds: 7 |
| Polar Surface Area: 54.46 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 8.08 | CX LogP: 3.32 | CX LogD: 2.56 |
| Aromatic Rings: 2 | Heavy Atoms: 29 | QED Weighted: 0.69 | Np Likeness Score: -1.81 |
References
| 1. Sniecikowska J,Gluch-Lutwin M,Bucki A,Więckowska A,Siwek A,Jastrzebska-Wiesek M,Partyka A,Wilczyńska D,Pytka K,Pociecha K,Cios A,Wyska E,Wesołowska A,Pawłowski M,Varney MA,Newman-Tancredi A,Kolaczkowski M. (2019) Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT Receptor-Biased Agonists with Robust Antidepressant-like Activity., 62 (5.0): [PMID:30721053] [10.1021/acs.jmedchem.9b00062] |
Source
Source(1):